Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective

BACKGROUND: In the phase III PACIFIC study, durvalumab improved survival versus placebo in patients with unresectable stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed after platinum-based concurrent chemoradiotherapy. The appraisal by the UK’s National Institute for Heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunlop, Will, van Keep, Marjolijn, Elroy, Peter, Perez, Ignacio Diaz, Ouwens, Mario J. N. M., Sarbajna, Tina, Zhang, Yiduo, Greystoke, Alastair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864051/
https://www.ncbi.nlm.nih.gov/pubmed/34532842
http://dx.doi.org/10.1007/s41669-021-00301-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864051/
https://www.ncbi.nlm.nih.gov/pubmed/34532842
http://dx.doi.org/10.1007/s41669-021-00301-7

Ejemplares similares